Safety and Efficacy of an Injectable Extracellular Matrix Hydrogel for Treating Myocardial Infarction
暂无分享,去创建一个
A. DeMaria | O. L. Kwan | Jennifer M. Singelyn | J. Dequach | S. Seif-Naraghi | Pamela J. Schup-Magoffin | K. Christman | N. Dib | R. Braden | K. Osborn | A. Kinsey | G. Strachan | Michael A. Salvatore | Jean J. Wang | Rebecca L. Braden | M. Preul | J. Wong | Unatti Sampat | Kendra Bartels
[1] K. Christman,et al. Injectable hydrogel therapies and their delivery strategies for treating myocardial infarction , 2013, Expert opinion on drug delivery.
[2] Kristin M. French,et al. A naturally derived cardiac extracellular matrix enhances cardiac progenitor cell behavior in vitro. , 2012, Acta biomaterialia.
[3] S. Seif-Naraghi,et al. Injectable extracellular matrix derived hydrogel provides a platform for enhanced retention and delivery of a heparin-binding growth factor. , 2012, Acta Biomaterialia.
[4] K. Christman. Treating the Leading Killer , 2012, Science Translational Medicine.
[5] Yi-Dong Lin,et al. Instructive Nanofiber Scaffolds with VEGF Create a Microenvironment for Arteriogenesis and Cardiac Repair , 2012, Science Translational Medicine.
[6] D. Hu,et al. Injectable skeletal muscle matrix hydrogel promotes neovascularization and muscle cell infiltration in a hindlimb ischemia model. , 2012, European cells & materials.
[7] A. DeMaria,et al. Catheter-deliverable hydrogel derived from decellularized ventricular extracellular matrix increases endogenous cardiomyocytes and preserves cardiac function post-myocardial infarction. , 2012, Journal of the American College of Cardiology.
[8] D. Mozaffarian,et al. Heart disease and stroke statistics--2012 update: a report from the American Heart Association. , 2012, Circulation.
[9] K. Christman,et al. Biomaterials for the treatment of myocardial infarction: a 5-year update. , 2011, Journal of the American College of Cardiology.
[10] M. Gyöngyösi,et al. Diagnostic and prognostic value of 3D NOGA mapping in ischemic heart disease , 2011, Nature Reviews Cardiology.
[11] K. Tobita,et al. Differential efficacy of gels derived from small intestinal submucosa as an injectable biomaterial for myocardial infarct repair. , 2010, Biomaterials.
[12] G. Keller,et al. Simple and High Yielding Method for Preparing Tissue Specific Extracellular Matrix Coatings for Cell Culture , 2010, PloS one.
[13] Hua-Lin Wu,et al. Intramyocardial Peptide Nanofiber Injection Improves Postinfarction Ventricular Remodeling and Efficacy of Bone Marrow Cell Therapy in Pigs , 2010, Circulation.
[14] Robert C Gorman,et al. Injectable hydrogel properties influence infarct expansion and extent of postinfarction left ventricular remodeling in an ovine model , 2010, Proceedings of the National Academy of Sciences.
[15] Kerry A. Daly,et al. Effect of the alphaGal epitope on the response to small intestinal submucosa extracellular matrix in a nonhuman primate model. , 2009, Tissue engineering. Part A.
[16] Jennifer M. Singelyn,et al. Naturally derived myocardial matrix as an injectable scaffold for cardiac tissue engineering. , 2009, Biomaterials.
[17] J. Leor,et al. Intracoronary injection of in situ forming alginate hydrogel reverses left ventricular remodeling after myocardial infarction in Swine. , 2009, Journal of the American College of Cardiology.
[18] K. Tobita,et al. Synthesis, characterization and therapeutic efficacy of a biodegradable, thermoresponsive hydrogel designed for application in chronic infarcted myocardium. , 2009, Biomaterials.
[19] K. Kuck,et al. Percutaneous intramyocardial stem cell injection in patients with acute myocardial infarction: first-in-man study , 2009, Heart.
[20] J. Gorman,et al. Allogeneic mesenchymal precursor cell therapy to limit remodeling after myocardial infarction: the effect of cell dosage. , 2009, The Annals of thoracic surgery.
[21] George P McCabe,et al. Macrophage phenotype and remodeling outcomes in response to biologic scaffolds with and without a cellular component. , 2009, Biomaterials.
[22] Li Zhang,et al. Degradation products of extracellular matrix affect cell migration and proliferation. , 2009, Tissue engineering. Part A.
[23] Mary A Whooley,et al. Prognostic value of left ventricular end-systolic volume index as a predictor of heart failure hospitalization in stable coronary artery disease: data from the Heart and Soul Study. , 2009, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.
[24] Christine N. Koval,et al. Targeted myocardial microinjections of a biocomposite material reduces infarct expansion in pigs. , 2008, The Annals of thoracic surgery.
[25] S. Houser,et al. Increased Cardiac Myocyte Progenitors in Failing Human Hearts , 2008, Circulation.
[26] Doris A Taylor,et al. Perfusion-decellularized matrix: using nature's platform to engineer a bioartificial heart , 2008, Nature Medicine.
[27] George P McCabe,et al. Extracellular matrix bioscaffolds for orthopaedic applications. A comparative histologic study. , 2006, The Journal of bone and joint surgery. American volume.
[28] Randall J Lee,et al. Biomaterials for the treatment of myocardial infarction. , 2006, Journal of the American College of Cardiology.
[29] E. Diethrich,et al. Safety and feasibility of percutaneous autologous skeletal myoblast transplantation in the coil-infarcted swine myocardium. , 2006, Journal of pharmacological and toxicological methods.
[30] E. Diethrich,et al. A percutaneous swine model of myocardial infarction. , 2006, Journal of pharmacological and toxicological methods.
[31] S. Solomon,et al. Heart failure on admission and the risk of stroke following acute myocardial infarction: the VALIANT registry. , 2005, European heart journal.
[32] Randall J Lee,et al. Injectable fibrin scaffold improves cell transplant survival, reduces infarct expansion, and induces neovasculature formation in ischemic myocardium. , 2004, Journal of the American College of Cardiology.
[33] M. Pfeffer,et al. VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context , 2003, European journal of heart failure.
[34] J. Pearlman,et al. Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: results of a phase I open-label dose escalation study. , 2000, Journal of the American College of Cardiology.
[35] F. Sellke,et al. Intracoronary and intravenous administration of basic fibroblast growth factor: myocardial and tissue distribution. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[36] R M Whitlock,et al. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. , 1987, Circulation.
[37] H. Kowarzyk. Structure and Function. , 1910, Nature.
[38] Donald O Freytes,et al. Reprint of: Extracellular matrix as a biological scaffold material: Structure and function. , 2015, Acta biomaterialia.
[39] X. Rabasseda,et al. A report from the American Heart Association Scientific Sessions 2011 (November 12-16, 2011, Orlando, Florida, USA). , 2012, Drugs of today.
[40] William R Wagner,et al. Intra-myocardial biomaterial injection therapy in the treatment of heart failure: Materials, outcomes and challenges. , 2011, Acta biomaterialia.
[41] Gerhard Nahler,et al. first-in-man study , 2009 .
[42] S. Badylak,et al. Extracellular matrix as a biological scaffold material: Structure and function. , 2009, Acta biomaterialia.